ARG was founded to provide small and mid—size biotech and pharmaceutical firms with high—quality clinical trial management services.

We've been down the clinical trial road many times. And we know that without a comprehensive map, a capable guide and a clear focus, the journey can be arduous. We believe that every company with promising, potentially life—enhancing products — no matter what the size — deserves the best possible chance to put their compounds to the test. And that these companies shouldn't be forced to rely on outdated, ill—suited services that add compromises, complexity and cost to a time—sensitive process.

Instead of heading down the path of least resistance, we enable our clients to follow the road of greatest reward.

Therapeutic Focus

Oncology, Immunology, Cardiovascular, Ophthalmology, Metabolic Disease, and Nephrology

Recent Trials

Multiple Phase III Immunology Studies

• Study 1 — pivotal study with 60 sites and 325 subjects
• Study 2 — open label study Part A with over 40 sites and 100 subjects
• Study 3 — open label study Part B with over 45 sites and 75 subjects
• Study 4 — PK study with 6 sites and 27 subjects

Phase II Ovarian Cancer study with 12 sites and 60 subjects
Phase II Nephrology study with 15 sites and 75 subjects.
Phase I Mesothelioma study with 3 sites and 25 subjects

Cumulative Experience

More than 70 clinical trials encompassing almost 3,000 investigative sites and over 40,000 subjects.